Pharmaceutical Executive, Dec 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Dec 1, 2010
Features
Diabetes: Agonists versus Inhibitors
By Walter Armstrong
Pharm Exec's Pipeline Report 2013
Nicotine Addiction: What Lights Up the Field
By Walter Armstrong
Pharm Exec's Pipeline Report 2018
Hyperlipidemia: The Anti-CETPs Redux
By Walter Armstrong
Pharm Exec's Pipeline Report 2011
Acute Coronary Syndrome
By Walter Armstrong
Pharm Exec's Pipeline Report 2012
Vaccines: Progress in Preventing Bad Bugs
By Walter Armstrong
Pharm Exec's Pipeline Report 2024
Cancer: On Target Once More
By Walter Armstrong
Pharm Exec's Pipeline Report 2019
HIV: Better Combos and Classes Keep Coming
By Walter Armstrong
Pharm Exec's Pipeline Report 2016
China 2020: Walled In No More
By Zhu Shen
Pharma sets the pace for China's ambitious new innovation agenda
Lupus: How Big will Benlysta Become?
By Walter Armstrong
Pharm Exec's Pipeline Report 2022
Multiple Sclerosis: The Advent of the Orals
By Walter Armstrong
Pharm Exec's Pipeline Report 2021
Hepatitis C: Another Protease Revolution
By Walter Armstrong
Pharm Exec's Pipeline Report 2015
Rheumatoid Arthritis: JAKing Down Inflammation
By Walter Armstrong
Pharm Exec's Pipeline Report 2023
The Next Wave: Pharm Exec's 2011 Pipeline Report
By Walter Armstrong
42 of the best new drugs in development–or parked at the FDA
Alzheimer's: A Disease at a Crossroads
By Walter Armstrong
Pharm Exec's Pipeline Report 2014
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator
By William Looney
Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office
Depression: A Not-So-Rosy Outlook
By Walter Armstrong
Pharm Exec's Pipeline Report 2017
Non-Small-Cell Lung Cancer: Targeting Pathways and Patients
By Walter Armstrong
Pharm Exec's Pipeline Report 2020
Columns
Taking Advantage of the Science Behind Marketing
Being strategic—and applying data tools effectively— will go along way in helping to produce analytics that drive sales
Patient Empowerment by Decision Making Literacy
The simpler the explanation of a disorder and its treatment, the better able a patient is to take proper care of himself
Is Euroland Following the US Disclosure Lead?
By William Looney
Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend
US Anti-Corruption Regulation Risks
By Anjali Chaturvedi , Brian K. French
Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance
New Ballgame in Washington
By Jill Wechsler
Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research
A New Twist in the Cost Curve
By Ansis Helmanis
The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?
Emerging Stakeholders with Clout: The Press Power Behind ProPublica
By William Looney
The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica
Adherence Equation: The Code is Cracked!
By Andrea LaFountain
Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine
Gentle Collisions in Marketing
Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your prouct into consumers' lives in a series of personal, non-invasive ways
From the Editor
In Through the Out Door
By William Looney
The end of anther year is an appropriate time to highlight the march of time—and the transitions that accompany it
Feature
PharmEssentia: The 30-Year Dream
A small company shows how it can play a major role in a relatively short time frame

ADVERTISEMENT

Click here